The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.

The safety results of ACASA-TAVI and NOTION-4 were discordant as well, Windecker said. “But please note that overall event numbers were very low, the treatment estimates are imprecise, and the ...